Share this @internewscast.com
Cann Group Limited has opened a state-of-the-art glass house in regional NSW to help meet future demand for medicinal cannabis.
Inside the facility, there’s the capacity to grow 250,000 cannabis plants.
“It’s a controlled environment glasshouse, very technologically advanced and going to be very important for the supply of product to Australian patients,” CEO of Cann Group Peter Crock said.
The manufacturing hub is based in Mildura and produces cannabidiol (CBD) capsules for Australian patients and for export.
A trial is now underway in hopes of making low-dose medicinal cannabis capsules more accessible for Australians, and the large manufacturing hub has been built to keep up with demand if this happens.
“The idea of making cannabinoids and CBD in particular available through pharmacy is a really important step,” Crock said.
Tammy Webber has volunteered to be part of a clinical trial of these CBD capsules to help relieve her insomnia.
“I can get to sleep okay but once I wake up about one, sometimes midnight, I just can’t get back to sleep at all,” Webber said.
The 53-year-old from Sydney’s south-west is desperate for a solution, as other treatments haven’t worked.
“It would be much better for my job, which involves a lot of driving around the daytime, just makes it hard if you’re tired,” she said.
The trial aims to produce enough evidence to have the capsules listed on the Australian Register of Therapeutic Goods and be available over the counter in pharmacies.
“If there are clear results, clear evidence in regards to this medicine helping patients with sleep-related issues, then yes it should be adequate to get the medicine over the counter,” authorised medicinal cannabis prescriber and GP Dr James Connell said.
Most medicinal cannabis products are currently not approved by Australia’s medical regulator, the Therapeutic Goods Administration, but are available through a special access scheme.
The most triple vaccinated countries on Earth